The influence of acetylation status of tuberculosis patients on the isoniazid serum concentrations and sputum conversion after intensive phase therapy

https://doi.org/10.19106/JMedSci005001201807

Dwi Indria Anggraini(1*), Erna Kristin(2), iwan Dwiprahasto(3)

(1) Department of Pharmacology, Faculty of Medicine, Lampung University, Tanjung Karang, LAMPUNG
(2) Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
(3) Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
(*) Corresponding Author

Abstract


Isoniazid (INH), one of the major antituberculosis drugs, is metabolized by acetylation. Previously study proved the significant differences of serum INH concentration between subject with fast and slow acetylation status. However, the correlation of acetylation status with treatment outcome after fixed-dose combination antituberculosis therapy (FDC-ATT) was not explained. The aim of this study was to evaluate the influence of acetylation status on the treatment outcome and the serum INH concentrations in the adult tuberculosis patients underwent FDC-ATT. A cross sectional study was carried out on 31 tuberculosis patients. Acetylation status was measured by spectrophotometer and serum INH concentration was measured by high performance liquid chromatography (HPLC). Sputum conversion assay was conducted by Ziehl Nelsen method. t-Test, chi square, Mann-Whitney, and Fisherman were used to analyze the data. The proportion of the fast acetylator was 61.3%, whereas the slow acetylator was 38.7%. The proportion of success and failure sputum conversion were 83.9% and 16.1%, respectively. The mean serum INH concentration in the fast acetylator groups (1.52 ± 0.15 μg/mL) was significantly lower than that in the slow acetylator groups (3.84 ± 0.35 μg/mL). The failure conversion risk of the fast acetylator group was about two folds higher than the slow acetylator group, although it was not significantly different (RR=2.53; 95% CI=0.32-20.00; p>0.05). Moreover, the mean serum INH concentration in success (2.46 ± 0.31 μg/mL) and failure (1.89 ± 0.20 μg/mL) sputum conversion was not significantly different (p>0.05). In conclusion, the acetylation status does not influence the sputum conversion in adult tuberculosis patients after FDC-ATT although the serum INH concentration on slow acetylation status is higher than that fast acetylation status.

 


Keywords


acetylation status; isoniazid level; success of therapy; conversion sputum; intensive phase treatment; tuberculosis

Full Text:

PDF


References

  1. Raviglione MC & O’Brien RJ. Tuberculosis. In: AS Fauci, DL Kasper, DL Longo, E Braunwald, SL Hauser, JL Lameson, J Loscalzo, editors.Harrison’s Principles of Internal Medicine. 17th edition. New York: Mc.Graw Hill Companies Inc, 2008: 1006-20.
  2. Lo Bue PA, Ademarco MF, Casatro KG. The epidemiology, prevention, and control of tuberculosis in the United States. In: AP Fishman, JA Elias, MA Grippi, RM Senior, and AI Pack, editors. Fishman’s Pulmonary Diseases and Disorders. Fourth edition. San Fransisco: Mc.Graw Hill Companies Inc, 2008: 2446-57.
  3. Depkes RI. Pedoman nasional penanggulangan tuberkulosis. Edisi 2, cetakan pertama. Jakarta: Departemen Kesehatan RI, 2007.
  4. World Health Organization. World Health Organization report 2009: Global tuberculosis control epidemiology, strategy, financing. Geneva: World Health Organization, 2009.
  5. Dinas Kesehatan Provinsi DI Yogyakarta. Profil kesehatan Propinsi DI Yogyakarta tahun 2008. Yogyakarta: Dinas Kesehatan Provinsi D I Yogyakarta, 2008.
  6. Swaminathan S, Narendran G. HIV and tuberculosis in India. J Biosci2008; 33:527–37. http://dx.doi.org/10.1007/s12038-008-0071-2
  7. Aditama, TY. XDR-TB. JTI 2006; 3(2):20-2.
  8. Rintiswati N, Dwianingsih EK, Rahman A, Iswanto, Rizal Y, Sumardi. Resistensi Mycobacterium tuberculosis terhadap beberapa obat anti tuberculosis pilihan utama dan pilihan kedua di Laboratorium Mikrobiologi FK UGM tahun 2000-2004. BIK 2005; 37(4):190-7.
  9. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. Should we use N-Acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49: 1733-8. http://dx.doi.org/10.1128/AAC.49.5.1733-1738.2005
  10. Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F, et al. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 2008; 33(2):187-95. http://dx.doi.org/10.2131/jts.33.187
  11. Ellard GA.Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976;19: 610-25. http://dx.doi.org/10.1002/cpt1976195part2610
  12. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005; 90: 614–8. http://dx.doi.org/10.1136/adc.2004.052175
  13. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341-7. http://dx.doi.org/10.1164/rccm.200208-951OC
  14. Yuliwulandari R, Sachrowardi Q, Nishida N, Takasu M, Batubara L, Susmiarsih TP, et al. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J Hum Genetics2008; 53:201–9. http://dx.doi.org/10.1007/s10038-007-0237-z
  15. Rao KVN, Mitchison DA, Nair NGK, Prema K, Tripathy SP. Sulphadimidine acetylation test for classification of patients as slow or rapid acetylators of isoniazid. Br Med J 1970; 3: 495497. http://dx.doi.org/10.1136/bmj.3.5721.495
  16. Santoso B, Sugiyanto, Asdie S, Effendi R. Absence of relationship between isoniazid-induced hepatic disturbances and acetylator phenotype. BKM 1991; 7 (3): 169-78.
  17. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic Drug Monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16(10): 1546-53. http://dx.doi.org/10.3201/eid1610.100374
  18. Kayhan S & Akgunes A. Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations. African J Pharm Pharmacol 2011; 5(17): 2035-41. http://dx.doi.org/10.5897/AJPP11.511
  19. Mah A, Kharrat H, Ahmed R, Gao Z, Der E, Hansen E, et al. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients. Int J Tuberc Lung Dis 2015; 19(2):2010-15. http://dx.doi.org/10.5588/ijtld.14.0405
  20. Dinas Kesehatan Provinsi DI Yogyakarta. Profil kesehatan Provinsi DI Yogyakarta 2008. Yogyakarta: Dinas Kesehatan Provinsi DI Yogyakarta, 2008.
  21. Ditah IC, Reacher M, Palmer C, Watson JM, Innes J, Kruijshaar ME, et al. Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective. Thorax 2008; 63:440-6. http://dx.doi.org/10.1136/thx.2006.073916
  22. World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
  23. Atif M, Sulaiman SAS, Shafie AA, Ali I, Asif M, Babar ZUD. Treatment outcome of new smear positive pulmonary tuberculosis patients in Penang, Malaysia. BMC Infect Dis 2014; 14:399. http://dx.doi.org/10.1186/1471-2334-14-399
  24. Conte JE, Golden, JA, McQuitty M, Kipps J, Duncan S, McKenna E et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Chemother 2002; 46 (8):2358-64.http://dx.doi.org/10.1128/AAC.46.8.2358-2364.2002
  25. Petri WA. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: L Brunton, J Lazo, and KL Parker, eds. Goodman and Gilman’s the Pharmacological Basic of Therapeutics. 11thedition. New York: Mc.Graw Hill Companies Inc, 2006; 1203-23.
  26. Roy V, Tekur U, Chopra K. Pharmacokinetics of isoniazid in pulmonary tuberculosis-a comparative study at two dose levels. Ind Pediatrics 1996;33:287-92.
  27. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentration of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Inf Dis2005; 41: 461-9.http://dx.doi.org/10.1086/431984



DOI: https://doi.org/10.19106/JMedSci005001201807

Article Metrics

Abstract views : 681 | views : 750




Copyright (c) 2018 Journal of the Medical Sciences (Berkala ilmu Kedokteran)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

View My Stats

 

Creative Commons License
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by  Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jurnal.ugm.ac.id/bik/.